EIF4E3

Summary

EIF4E3 (eukaryotic translation initiation factor 4E family member 3, HGNC:31837) is a protein-coding gene on chromosome 3p13, encoding Eukaryotic translation initiation factor 4E type 3 (Q8N5X7). Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis.

EIF4E3 belongs to the EIF4E family of translational initiation factors that interact with the 5-prime cap structure of mRNA and recruit mRNA to the ribosome (Joshi et al., 2004 [PubMed 15153109]).

Source: NCBI Gene 317649 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 86 total — 2 pathogenic
• MANE Select transcript: NM_001134651

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31837
Approved symbol	EIF4E3
Name	eukaryotic translation initiation factor 4E family member 3
Location	3p13
Locus type	gene with protein product
Status	Approved
Aliases	MGC39820
Ensembl gene	ENSG00000163412
Ensembl biotype	protein_coding
OMIM	609896
Entrez	317649

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000295612, ENST00000389826, ENST00000421769, ENST00000425534, ENST00000448225, ENST00000468147, ENST00000469524, ENST00000481525, ENST00000496214, ENST00000497838, ENST00000859497, ENST00000948192

RefSeq mRNA: 5 — MANE Select: NM_001134651 NM_001134649, NM_001134650, NM_001134651, NM_001282886, NM_173359

CCDS: CCDS33786, CCDS46867

Canonical transcript exons

ENST00000425534 — 7 exons

Exon	Start	End
ENSE00001252440	71696460	71696520
ENSE00001746209	71725192	71725402
ENSE00001858849	71675414	71684728
ENSE00003535120	71710412	71710484
ENSE00003577786	71699614	71699708
ENSE00003685646	71690010	71690165
ENSE00003785554	71693875	71693941

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 96.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.1634 / max 475.9939, expressed in 1496 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43095	9.0212	1471
43101	0.4708	261
43100	0.2370	93
43097	0.1178	61
43102	0.1068	60
43098	0.1061	60
43103	0.0759	41
43096	0.0278	19

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	96.74	gold quality
tibialis anterior	UBERON:0001385	96.08	gold quality
deltoid	UBERON:0001476	95.39	gold quality
ileal mucosa	UBERON:0000331	95.17	gold quality
monocyte	CL:0000576	94.81	gold quality
leukocyte	CL:0000738	94.59	gold quality
left ventricle myocardium	UBERON:0006566	94.44	gold quality
skeletal muscle tissue	UBERON:0001134	93.54	gold quality
quadriceps femoris	UBERON:0001377	93.54	gold quality
skeletal muscle organ	UBERON:0014892	93.23	gold quality
muscle of leg	UBERON:0001383	93.17	gold quality
gastrocnemius	UBERON:0001388	93.17	gold quality
vastus lateralis	UBERON:0001379	93.10	gold quality
biceps brachii	UBERON:0001507	92.69	gold quality
muscle tissue	UBERON:0002385	92.55	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.55	gold quality
cardiac muscle of right atrium	UBERON:0003379	92.51	gold quality
secondary oocyte	CL:0000655	92.50	gold quality
blood	UBERON:0000178	92.23	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.12	gold quality
myocardium	UBERON:0002349	91.27	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.24	gold quality
bone marrow	UBERON:0002371	90.12	gold quality
bone marrow cell	CL:0002092	90.09	gold quality
prefrontal cortex	UBERON:0000451	89.75	gold quality
colonic epithelium	UBERON:0000397	89.66	gold quality
epithelial cell of pancreas	CL:0000083	89.49	gold quality
parotid gland	UBERON:0001831	89.40	gold quality
calcaneal tendon	UBERON:0003701	89.05	gold quality
islet of Langerhans	UBERON:0000006	88.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

210 targeting EIF4E3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753

Literature-anchored findings (GeneRIF, showing 6)

• eIF4E3 impedes oncogenic transformation and its expression is lost in some cancers. (PMID:23587918)
• MNK1 and MNK2 inhibition ablates eIF4E1 phosphorylation and concurrently enhances eIF4E3 expression in diffuse large B-cell lymphoma. (PMID:25403230)
• Following heat shock, eIF4E2 is found in both processing bodies and stress granules, whereas eIF4E3_A relocates only to stress granules. (PMID:27578149)
• We performed bioinformatics analyses of ESTs and the 3’UTRs of the main transcript splice variants of the translational initiation factor eIF4E1 and its family members, eIF4E2 and eIF4E3. We propose to elucidate the minor splice variants of eIF4E2 and eIF4E3 in great detail because they might produce proteins with modified features that fulfill different cellular roles from their major counterparts. (PMID:28942592)
• eIF4E3 forms an active eIF4F complex during stresses (eIF4FS) targeting mTOR and re-programs the translatome. (PMID:33893802)
• m7G-related genes-NCBP2 and EIF4E3 determine immune contexture in head and neck squamous cell carcinoma by regulating CCL4/CCL5 expression. (PMID:37067401)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	eif4e3	ENSDARG00000005078
mus_musculus	Eif4e3	ENSMUSG00000093661
rattus_norvegicus	Eif4e3	ENSRNOG00000010301
drosophila_melanogaster	eIF4E1	FBGN0015218
drosophila_melanogaster	eIF4E4	FBGN0035709
drosophila_melanogaster	eIF4E5	FBGN0035823
drosophila_melanogaster	eIF4E6	FBGN0039622
drosophila_melanogaster	eIF4E7	FBGN0040368
drosophila_melanogaster	eIF4EHP	FBGN0053100
drosophila_melanogaster	eIF4E3	FBGN0265089
caenorhabditis_elegans		WBGENE00002059
caenorhabditis_elegans		WBGENE00002062
caenorhabditis_elegans		WBGENE00002063

Paralogs (3): EIF4E2 (ENSG00000135930), EIF4E (ENSG00000151247), EIF4E1B (ENSG00000175766)

Protein

Protein identifiers

Eukaryotic translation initiation factor 4E type 3 — Q8N5X7 (reviewed: Q8N5X7)

All UniProt accessions (4): C9J6E5, C9J7Z6, C9JUY2, Q8N5X7

UniProt curated annotations — full annotation on UniProt →

Function. Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis. May act as an inhibitor of EIF4E1 activity.

Subunit / interactions. eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least eIF4A, eIF4E and eIF4G. EIF4E3 interacts with EIF4G1, but not with EIF4EBP1, EIF4EBP2 and EIF4EBP3.

Similarity. Belongs to the eukaryotic initiation factor 4E family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N5X7-1	1	yes
Q8N5X7-2	2

RefSeq proteins (5): NP_001128121, NP_001128122, NP_001128123, NP_001269815, NP_775495 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001040	TIF_eIF_4E	Family
IPR023398	TIF_eIF4e-like	Homologous_superfamily

Pfam: PF01652

UniProt features (6 total): binding site 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N5X7-F1	80.02	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 115–116; 169–174

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1169408	ISG15 antiviral mechanism
R-HSA-9918487	Dengue Virus Genome Translation and Replication

MSigDB gene sets: 188 (showing top): BENPORATH_ES_WITH_H3K27ME3, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_TRANSLATIONAL_INITIATION, GOMF_TRANSLATION_INITIATION_FACTOR_ACTIVITY, BEIER_GLIOMA_STEM_CELL_DN, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GGGCATT_MIR365, chr3p13, ATTCTTT_MIR186, ATGCTGG_MIR338, ACTTTAT_MIR1425P, DOUGLAS_BMI1_TARGETS_UP

GO Biological Process (3): translational initiation (GO:0006413), regulation of translation (GO:0006417), translation (GO:0006412)

GO Molecular Function (4): RNA 7-methylguanosine cap binding (GO:0000340), translation initiation factor activity (GO:0003743), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (2): cytosol (GO:0005829), eukaryotic translation initiation factor 4F complex (GO:0016281)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Antimicrobial mechanism of IFN-stimulated genes	1
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
translation	2
translational initiation	2
cytoplasm	2
formation of translation initiation ternary complex	1
metabolic process	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
peptidyltransferase activity	1
translational elongation	1
translational termination	1
macromolecule biosynthetic process	1
protein metabolic process	1
protein biosynthetic process	1
RNA cap binding	1
translation factor activity	1
nucleic acid binding	1
binding	1
cellular anatomical structure	1
RNA cap binding complex	1

Protein interactions and networks

STRING

2076 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EIF4E3	EIF4G1	Q04637	915
EIF4E3	EIF4A1	P04765	830
EIF4E3	EIF4G3	O43432	785
EIF4E3	EIF4EBP1	Q13541	721
EIF4E3	YTHDF1	Q9BYJ9	685
EIF4E3	EIF3D	O15371	660
EIF4E3	EIF5B	O60841	603
EIF4E3	GPR27	Q9NS67	580
EIF4E3	PABPN1	Q86U42	574
EIF4E3	EIF4EBP2	Q13542	535
EIF4E3	MAGOH	P50606	517
EIF4E3	MAGOHB	Q96A72	513
EIF4E3	EIF4E2	O60573	502
EIF4E3	CASC3	O15234	473
EIF4E3	EIF4G2	P78344	463

IntAct

8 interactions, top by confidence:

A	B	Type	Score
DCC	NTN1	psi-mi:“MI:0914”(association)	0.700
EIF4A1	EIF3D	psi-mi:“MI:0914”(association)	0.530
BMP2K	EIF4E3	psi-mi:“MI:0915”(physical association)	0.490
CFTR	EIF4E3	psi-mi:“MI:0915”(physical association)	0.370
EIF4E3	TBC1D4	psi-mi:“MI:0914”(association)	0.350
EIF4E3	fliP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): TBC1D4 (Affinity Capture-MS), THEMIS2 (Affinity Capture-MS), EIF4E3 (Synthetic Lethality), THEMIS2 (Affinity Capture-MS), TBC1D4 (Affinity Capture-MS), EIF4E3 (Affinity Capture-MS), EIF4E3 (Two-hybrid), EIF4E3 (Affinity Capture-MS), THEMIS2 (Affinity Capture-MS), TBC1D4 (Affinity Capture-MS), EIF4E3 (PCA), CTNNB1 (Affinity Capture-RNA), EIF4E3 (Affinity Capture-Western), EIF4E3 (Affinity Capture-Western), EIF4E3 (Affinity Capture-Western)

ESM2 similar proteins: A0JN27, A0PJN4, A1L167, A1L3K1, A2ADY9, B5DFI8, C1C3R6, D3Z7P3, G3MWR8, O43741, O88508, O94925, P13264, Q07G17, Q12800, Q13888, Q16763, Q1LZ53, Q1RML1, Q28D01, Q28F89, Q2KJ29, Q2TBV5, Q3MHJ2, Q4R9A8, Q4W5Z4, Q5NVP9, Q5R532, Q5RBN9, Q5SP67, Q5TDH0, Q66H54, Q6AYU1, Q6P1K8, Q6PAM0, Q76EZ2, Q7L5Y9, Q7RTP6, Q86TJ2, Q8AVU2

Diamond homologs: A0A075QQ08, A0A1D8EJF9, A0A1U8F5V2, A0A1U8GR65, A0A2J6L8Y7, A0A3Q7FGP1, A0A3Q7I7R4, A0A445AGS0, A3RCV9, A6NMX2, A7KWF8, C6ZJZ3, C7SG33, D3UW26, K0P2S0, M1J8U6, M1JJT8, O04663, O23252, O45551, O60573, O61955, O74743, O77210, O81481, O81482, P06730, P07260, P0DXI0, P0DXI5, P29338, P29557, P48597, P48598, P48599, P48600, P56570, P63073, P63074, P78954

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

86 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	70
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
148629	GRCh38/hg38 3p13(chr3:70943620-71861889)x1	Pathogenic
3062672	GRCh37/hg19 3p13(chr3:70583776-72793789)x1	Pathogenic

SpliceAI

1204 predictions. Top by Δscore:

Variant	Effect	Δscore
3:71690003:CACTT:C	donor_loss	1.0000
3:71690004:ACTTA:A	donor_loss	1.0000
3:71690005:CTTA:C	donor_loss	1.0000
3:71690006:TTA:T	donor_loss	1.0000
3:71690007:T:TC	donor_loss	1.0000
3:71690008:A:AC	donor_gain	1.0000
3:71690008:ACGTT:A	donor_loss	1.0000
3:71690009:C:A	donor_loss	1.0000
3:71690009:C:CG	donor_gain	1.0000
3:71690009:CG:C	donor_gain	1.0000
3:71690009:CGT:C	donor_gain	1.0000
3:71690009:CGTT:C	donor_gain	1.0000
3:71690009:CGTTT:C	donor_gain	1.0000
3:71690162:TCAT:T	acceptor_gain	1.0000
3:71690163:CAT:C	acceptor_gain	1.0000
3:71690163:CATC:C	acceptor_gain	1.0000
3:71690164:AT:A	acceptor_gain	1.0000
3:71690165:TC:T	acceptor_loss	1.0000
3:71690166:C:CC	acceptor_gain	1.0000
3:71690166:CT:C	acceptor_loss	1.0000
3:71710501:A:T	acceptor_gain	1.0000
3:71690161:ATCAT:A	acceptor_gain	0.9900
3:71690178:C:CT	acceptor_gain	0.9900
3:71690179:A:T	acceptor_gain	0.9900
3:71691706:A:C	acceptor_gain	0.9900
3:71691708:T:C	acceptor_gain	0.9900
3:71693947:A:C	acceptor_gain	0.9900
3:71710500:C:CT	acceptor_gain	0.9900
3:71710505:C:CT	acceptor_gain	0.9900
3:71725186:CCTCA:C	donor_loss	0.9900

AlphaMissense

1437 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:71690106:A:G	W178R	0.999
3:71690106:A:T	W178R	0.999
3:71690143:A:C	S165R	0.999
3:71690143:A:T	S165R	0.999
3:71690145:T:G	S165R	0.999
3:71693932:A:G	W139R	0.999
3:71693932:A:T	W139R	0.999
3:71684706:A:C	F217L	0.998
3:71684706:A:T	F217L	0.998
3:71684708:A:G	F217L	0.998
3:71690114:A:T	V175D	0.998
3:71690141:A:T	V166D	0.998
3:71690150:C:T	G163E	0.998
3:71696489:A:G	W126R	0.998
3:71696489:A:T	W126R	0.998
3:71696520:C:A	W115C	0.998
3:71696520:C:G	W115C	0.998
3:71699648:A:C	Y104D	0.998
3:71699702:A:G	W86R	0.998
3:71699702:A:T	W86R	0.998
3:71690011:T:A	K209N	0.997
3:71690011:T:G	K209N	0.997
3:71690016:A:C	Y208D	0.997
3:71690017:A:C	F207L	0.997
3:71690017:A:T	F207L	0.997
3:71690019:A:G	F207L	0.997
3:71690104:C:A	W178C	0.997
3:71690104:C:G	W178C	0.997
3:71690108:A:T	V177D	0.997
3:71690137:A:C	S167R	0.997

dbSNP variants (sampled 300 via entrez): RS1000025866 (3:71728605 G>C), RS1000123616 (3:71696861 G>A), RS1000135104 (3:71720463 G>A), RS1000166597 (3:71721575 T>C), RS1000190302 (3:71712012 C>T), RS1000208414 (3:71725680 T>C), RS1000236470 (3:71755752 G>A), RS1000239523 (3:71726018 G>A), RS1000327646 (3:71723500 A>G), RS1000345851 (3:71739029 A>G), RS1000361277 (3:71674570 G>A), RS1000373700 (3:71678731 T>C), RS1000377169 (3:71717437 C>A,T), RS1000383922 (3:71698935 T>C), RS1000401981 (3:71720356 C>T)

Disease associations

OMIM: gene MIM:609896 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST003999_1	Nose size	8.000000e-26
GCST004608_77	Granulocyte percentage of myeloid white cells	1.000000e-11
GCST004609_113	Monocyte percentage of white cells	2.000000e-14
GCST007576_379	Chronotype	1.000000e-08
GCST007576_69	Chronotype	6.000000e-12
GCST008114_21	Type 2 diabetes	5.000000e-06
GCST009066_5	Mosaic loss of chromosome Y (Y chromosome dosage)	2.000000e-09
GCST009067_7	Mosaic loss of chromosome Y (Y chromosome dosage)	1.000000e-24
GCST009391_1118	Metabolite levels	1.000000e-06
GCST009391_150	Metabolite levels	3.000000e-06
GCST009391_983	Metabolite levels	9.000000e-06
GCST010148_5	Cutaneous squamous cell carcinoma	2.000000e-09
GCST010241_367	Apolipoprotein A1 levels	8.000000e-11
GCST010242_46	HDL cholesterol levels	8.000000e-15
GCST90002393_240	Monocyte count	3.000000e-16
GCST90002394_246	Monocyte percentage of white cells	9.000000e-24

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0007997	granulocyte percentage of myeloid white cells
EFO:0007989	monocyte percentage of leukocytes
EFO:0008328	chronotype measurement
EFO:0007783	mosaic loss of chromosome Y measurement
EFO:0010523	phosphoglyceric acid measurement
EFO:0010476	dimethylglycine measurement
EFO:0010538	taurocholate measurement
EFO:1001927	cutaneous squamous cell carcinoma
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	5
trichostatin A	affects cotreatment, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
aristolochic acid I	decreases expression	1
sotorasib	affects cotreatment, decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases methylation, affects cotreatment	1
sodium arsenate	increases abundance, decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
sulforaphane	increases expression	1
sodium arsenite	increases expression	1
nickel chloride	affects cotreatment, increases expression	1
potassium chromate(VI)	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	increases abundance, decreases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	decreases methylation, increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_IN95	HLY-1 eIF4E3	Cancer cell line	Sex unspecified

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.